99
Participants
Start Date
November 25, 2020
Primary Completion Date
December 22, 2022
Study Completion Date
December 22, 2022
Faricimab
A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
Long Is. Vitreoretinal Consult, Hauppauge
Ospedale San Giuseppe; U.O. Oculistica, Milan
Irccs Ospedale San Raffaele;U.O. Oculistica, Milan
Cumberland Valley Retina PC, Hagerstown
Bascom Palmer Eye Institute, Naples
Charles Retina Institute, Germantown
Raj K. Maturi, MD PC, Indianapolis
University Retina and Macula Associates, PC, Oak Forest
Northwestern Medical Group/Northwestern University, Chicago
The Retina Institute, St Louis
Universitätsklinikum Tübingen, Tübingen
Strategic Clinical Research Group, LLC, Willow Park
Austin Research Center for Retina, Austin
Retina Res Institute of Texas, Abilene
Retina Consultants of Texas, The Woodlands
Centro Oftalmológico Dr. Charles S.A., Capital Federal
Oftalmos, Capital Federal
Vitreous Retina Macula Specialists of Toronto, Etobicoke
The Retina Centre of Ottawa, Ottawa
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy, Warsaw
Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire
Kings College Hospital, London
Sunderland Eye Infirmary, Sunderland
Hoffmann-La Roche
INDUSTRY